In a patient with an intracerebral hemorrhage who is on aspirin and clopidogrel for stent protection, how should antiplatelet therapy be managed?

Management of Antiplatelet Therapy in Intracerebral Hemorrhage with Coronary Stents

Immediate Action: Stop Both Antiplatelet Agents

In a patient with intracerebral hemorrhage on dual antiplatelet therapy for stent protection, immediately discontinue both aspirin and clopidogrel regardless of stent type or timing. The mortality risk from ongoing hemorrhage expansion far exceeds the risk of stent thrombosis in this acute setting. 1

---

Risk Assessment Framework

Hemorrhage Risk Factors

• Obtain urgent non-contrast CT to quantify hematoma volume and assess for active bleeding (contrast extravasation). Hematoma expansion occurs in approximately 38% of patients on antiplatelet therapy and typically happens within the first 6 hours. 2
• Check hemoglobin, platelet count, and coagulation parameters immediately. 3
• Assess neurological status with Glasgow Coma Scale and document any deterioration. 3

Stent Thrombosis Risk Factors

• Time since stent placement is the most critical variable:
  • <30 days post-stent = extremely high thrombosis risk 4
  • 30 days to 12 months = high risk for drug-eluting stents 5

  • 12 months = moderate risk 5

• Stent characteristics that increase thrombosis risk: multiple stents, long stents, bifurcation stents, history of prior stent thrombosis, incomplete revascularization, diabetes, low ejection fraction 5

---

Platelet Transfusion: Not Recommended

Do not routinely transfuse platelets in patients with intracerebral hemorrhage who were taking aspirin or clopidogrel. A retrospective study of 66 patients showed no reduction in hematoma expansion rates with platelet transfusion (no statistically significant difference between transfused vs. non-transfused cohorts), and platelet transfusion may paradoxically increase thrombotic risk by releasing ADP. 2, 3, 6

• Exception: Consider platelet transfusion only if urgent neurosurgical intervention is required and the patient has documented severe thrombocytopenia. 3

---

Multidisciplinary Decision-Making

Convene an urgent multidisciplinary team meeting within 24 hours including the neurologist/neurosurgeon, interventional cardiologist, hematologist, and intensivist. This team should jointly assess:

• The risk of continued hemorrhage expansion if antiplatelets are withheld 5
• The risk of catastrophic stent thrombosis leading to myocardial infarction and death 4
• Whether the hemorrhage requires surgical evacuation 3
• The optimal timing for resuming antiplatelet therapy 5

Document all decisions in the medical record with clear rationale. 5

---

Timing of Antiplatelet Resumption

For Patients <30 Days Post-Stent (Highest Risk)

• Resume aspirin 75-100 mg daily as soon as hemorrhage stability is confirmed (typically 48-72 hours after ictus if repeat CT shows no expansion and hemoglobin is stable). 4, 6
• Consider resuming clopidogrel 75 mg daily at 3-5 days if hematoma remains stable, recognizing this represents a balance between competing catastrophic risks. 6
• Do not reload with clopidogrel 300-600 mg—resume at maintenance dose only, as reloading after brief interruption provides no additional platelet inhibition but markedly increases hemorrhagic risk. 1

For Patients 1-12 Months Post-Drug-Eluting Stent

• Resume aspirin 75-100 mg daily at 5-7 days if imaging confirms hemorrhage stability. 5, 4
• Resume clopidogrel 75 mg daily at 7-10 days if no rebleeding and neurological status is stable or improving. 5
• Maintain dual antiplatelet therapy for the originally planned duration (typically 12 months for drug-eluting stents). 5

For Patients >12 Months Post-Stent

• Resume aspirin 75-100 mg daily at 7-14 days once hemorrhage is clearly stable. 4
• Clopidogrel can be permanently discontinued in most cases, as the critical period for stent thrombosis has passed. Continue aspirin monotherapy indefinitely. 4

---

Bridging with Anticoagulation: Not Recommended

Do not bridge with heparin or low-molecular-weight heparin during the antiplatelet interruption period in patients with intracerebral hemorrhage. The French Task Force recommendation for heparin bridging applies only to elective surgical procedures with low hemorrhagic risk, not to active intracranial bleeding. 5, 4

---

Supportive Management During Antiplatelet Hold

• Maintain systolic blood pressure <140 mmHg (target 130-140 mmHg) to minimize hematoma expansion risk. Avoid excessive blood pressure reduction that could compromise cerebral perfusion. 3
• Avoid red blood cell transfusion unless hemoglobin <7 g/dL or hemodynamic instability persists, as transfusion releases ADP and paradoxically increases platelet reactivity. 6
• Initiate proton pump inhibitor therapy intravenously to reduce future gastrointestinal bleeding risk when antiplatelets are resumed. 6
• Avoid NSAIDs, anticoagulants, and other medications that increase bleeding risk. 6

---

Special Consideration: Clopidogrel Resistance

• Recognize that approximately 66% of patients on clopidogrel do not achieve adequate platelet inhibition even with standard dosing, which may paradoxically reduce hemorrhage expansion risk but also limits stent protection. 7, 8
• Do not perform platelet function testing during the acute hemorrhage phase, as management decisions are driven by clinical stability, not laboratory values. 7, 8

---

Critical Pitfalls to Avoid

• Never resume both antiplatelet agents simultaneously in the first week—stagger resumption with aspirin first, then clopidogrel 2-3 days later if stable. 6
• Never use a clopidogrel loading dose (300-600 mg) when resuming therapy after hemorrhage—this dramatically increases rebleeding risk without benefit. 1
• Never delay urgent cardiology consultation beyond 24 hours—stent thrombosis can occur rapidly and is often fatal. 4
• Never continue both agents indefinitely without reassessing the indication—dual therapy beyond 12 months post-stent increases major bleeding risk (HR 2.22-2.32) without additional benefit. 1